fied S. typhi or S. marcescens endotoxin, or their corresponding purified lipid A components. All of the vaccinated mice (except for saline-or thioglycolate-injected controls) exhibited increased protection against the lethal intraperitoneal challenge with S. typhi Ty2. Serial quantitative bacterial counts carried out on peritoneal washouts and on homogenates of the draining mediastinal lymph nodes indicated the development of an antibacterial response by the vaccinated host which was not observed in the control animals. Mice receiving purified endotoxin (lipopolysaccharide) exhibited varying degrees of protection, both in terms of increased host survival and the amount of inactivation of the challenge population in vivo. The response seen when the antigenically unrelated S. marcescens lipopolysaccharide was injected was little different from that seen when the acetone-killed S. typhi Ty2 whole-cell vaccine was used. This suggests that nonspecific inactivation of the intraperitoneal challenge contributes substantially to the immune response seen in mice vaccinated intraperitoneally with specific typhoid antigens.
Salmonella typhi is an obligate human pathogen which, unlike Salmonella typhimurium, does not induce a progressive systemic infection when introduced into nornal mice (2, 4) . In intraperitoneally (i.p.) or intravenously (i.v.) infected white mice, 106 viable S. typhi results in a short-lived, usually nonlethal infection (11) , which makes it difficult to demonstrate the development of an accelerated antibacterial immune response in actively immunized animals (5) . Massive i.p. inocula result in the development of an overwhelming peritonitis (11) , with death occurring within 24 h of challenge; such an infection pattern bears little resemblance to that seen in naturally infected human beings (24) . This difference in growth behavior has caused some workers to question the relevance of the present laboratory assay system, or its ability to predict the protective qualities of a given typhoid vaccine against the naturally acquired human disease (20, 21) accurately. The i.p. challenge method assesses opsonic and antitoxic antibody responses to the somatic antigens in the vaccine strain (4) but will not evaluate the involvement of any cellular immune response of the type that develops in actively infected individuals recovering from the disease (5, 8, 23) .
Despite the extensive use of laboratory assays for human typhoid vaccines (12, 16, 20, 21) , mere death or survival of the challenged host tells us very little about the protective mechanism per se. To determine this, we must follow the in vivo behavior of the challenge population in the vaccinated host throughout the challenge period (5) . Surprisingly, we know remarkably little about the quantitative growth behavior of S. typhi in the reticuloendothelial organs of normal mice, regardless of whether the i.p. (11) , oral (10) Bacterial enumeration technique. At necropsy, the livers, spleens, and mediastinal lymph nodes were removed aseptically from five randomly selected animals for each time point. The tissues were homogenized individually in sterile saline, and appropriate dilutions were plated on TSA (2). The colonies were counted after 24 h of incubation at 37°C. The peritoneal cavities were washed out with 2.5 ml of cold sterile saline (1) before the other tissues were removed. The peritoneal washout was diluted in saline, samples were plated on TSA, and the number of viable bacteria was determined.
Vaccines. Commercial acetone-killed S. typhi vaccine (109 bacilli per ml) was purchased from Eli Lilly & Co., Indianapolis, Ind. S. typhi 0-901, Y. enterocolitica WA, and S. marcescens vaccines were prepared from lawns grown on TSA at 30°C and were scraped off into sterile saline before the cells were centrifuged at 10,000 x g for 20 min at 4°C and resuspended in acetone. The suspensions were incubated overnight at 37°C with agitation, washed three times in saline, and resuspended to a concentration of approximately 109 bacilli per ml in sterile phosphate-buffered saline containing 1:1,000 Merthiolate (Eli Lilly & Co.). Sterility was checked by culturing 2 
RESULTS
Growth of typhoid bacilli in i.v. and i.p. infected normal mice. Infection of normal B6D2 mice with 5 x 106 viable S. typhi i.v. was followed by a 90 to 99% decline in bacterial viability over the first few hours, which then continued at an almost linear rate of decline until viable bacilli could no longer be detected in the liver by day 14 (Fig. 1) . The corresponding spleen counts increased from 104 bacilli on day 1 to nearly 105 viable bacilli per organ by day 7, followed by a slow decline thereafter. Several hundred viable S. typhi could still be detected in the spleen 3 or 4 weeks after infection.
Much the same growth pattern was observed when the same inoculum was introduced i.p. (Fig. 1) . Here the injected bacteria were rapidly inactivated within the peritoneal cavity, which was free of infection by day 11. The draining mediastinal lymph nodes became heavily infected by 24 h, but thereafter the viability declined at much the same rate as that seen in the liver. Once again, the spleen showed an early growth phase followed by a slow decline (Fig. 1) Table  1 ). Mice that had received 0.5 ml of sterile pyrogen-free saline or thioglycolate broth i.p. 7 days earlier also exhibited 100% death rates over the first 24-h challenge period. Those mice that received 200 ,ug of C. parvum vaccine showed no better levels of protection, despite the fact that this agent increases both macrophage numbers and activity in vivo (5) . The number of viable S. typhi recovered from the peritoneal cavities of these nonspecifically stimulated mice 10 min after challenge was virtually the same in all cases (Table 1) . Only the C. parvum-treated animals seemed able to limit the growth of the S. typhi in the mediastinal lymph nodes, but, despite this, all of the C. parvum mice were dead by 48 h.
Growth of typhoid bacilli in specifically immunized mice. The protective effect of commercial typhoid vaccine, as well as of the acetone-killed S. typhi 0-901 preparation, was considerable, both in terms of overall host survival and in the limitation of the bacterial growth in vivo over the first 72 h (Table 2) . Initially, the mediastinal node counts showed some increase, but by 4 (Table 3) .
Lipid A has been reported to be responsible for much of the toxicity of the endotoxin molecule (18) . It was interesting, therefore, to inject mice with 100 or 200 jig of purified lipid A. Neither test concentration of lipid A conferred any protection against the subsequent S. typhi challenge, however (Table 3 ). Even when the lipid A was complexed to bovine serum albumin (9, 18) , no increase in survival could be demonstrated. Controls indicated that the residual triethylamine present in the lipid A emulsion was without any apparent effect either. Other control mice given whole S. typhi Ty2 vaccine or purified Ty2 LPS were both fully protected against the lethal effects of the smallest challenge dose. Increasing the challenge inoculum 10-fold resulted in the death of all of the mice vaccinated with the killed vaccine, but not the mice given the large dose of LPS (Table 3) .
Growth of typhoid bacilli in mice receiving an antigenically pnrelated vaccine. In view of the increased resistance expressed by mice receiving the Serratia endotoxin, the effect of 108 heat-killed S. marcescens or Y. enterocolitica was examined. Clearance of the S. typhi Ty2 from the peritoneal cavities of both groups of mice was not affected over the first 4 h of the infection (Table 4) , but then the number of viable typhoid bacilli recovered from the mediastinal lymph nodes of the Yersiniatreated mice was seen to be significantly lower than in the concurrent control animals (recorded in Table 1 ). Complete protection was again observed in both groups of animals. Clearly, other factors besides the induction of (4) .
There is no question that the killed S. typhi vaccine increases resistance to an i.p. challenge with living S. typhi Ty2 (Table 2) . However, as noted earlier (12, 16, 20) , optimum protection VoL 17, 1977 1lo killed S. typhi whole cells will introduce an appreciable amount of endotoxin into the pentoneal cavity, with the likelihood that a measurable, persistent effect will be observed even 7 days later (14) . The data shown in Tables 2 and  3 indicate that the endotoxins associated with the typhoid vaccine do, in fact, produce such an effect. There is no question that the smooth somatic (and possibly Vi) antigens result in the production of specific antibodies, although the serum titers should still be quite low at the time of the 7-day challenge (15) . However, they could exert some specific protective effect against the i.p. challenge (1, 14, 16) and thus contribute to the overall host survival. Taken together, the various responses to the i.p. introduced vaccine are clearly able to substantially increase host reistance to the challenge. Such an immunization protocol using killed Salmonella provides only marginally increased protection against an oral (17) or i.v. challenge, however (5). Protection studies (7) using massive oral challenge inocula demonstrated a slight advantage over control mice when growth or inactivation of the challenge inoculum within the livers and spleens was used as the means of asg the vaccines (8) .
One of the most interesting points to arise from the present study is the increased survival observed after the introduction of as little as 10 ,ug of purified LPS into the peritoneal cavity 7 days before challenge ( Table 3 ). The LPS response undoubtedly included some nonspecific element, since the Serratia endotoxin also afforded considerable protection against the S. typhi challenge (Table 3 ). In the light of this data, a specific protective role for both the somatic and Vi antigens of S. typhi, based largely as it is on the i.p. infected mouse test system, should perhaps be reevaluated (23) . Differences between the high protective indexes obtained from some vaccine preparations evaluated by means of the mouse protection test and the actual level of protection achieved in field trials against the naturally acquired human disease are perhaps not so surprising (12, 18, 23 (7) . The i.p. route of challenge is inappropriate for the assessment of a vaccine that is to be used to prevent the development of an orally induced disease (1, 8, 23) , and a better assay method is clearly required.
